Primary and secondary prevention of ischemic stroke (IS) benefits from antiplatelet and anticoagulant therapies.2However, compared with coronary heart diseases (CHDs), P2Y12 inhibitors other than clopidogrel have no clinical use in primary stroke prevention and can be contraindicated (prasugrel) in patients with a previous stroke for increased risk of intracranial bleeding.3Similarly, dual antiplatelet therapy (DAPT) is effective just in the early phases of the IS (21–30 days) before becoming useless or detrimental. This evidence concerns the gene P2RY12 and Stroke.